ONL Therapeutics Initiates Phase 2 GALAXY Trial for Xelafaslatide
ONL Therapeutics has randomized the first patient in its phase 2 GALAXY trial, evaluating xelafaslatide for geographic atrophy associated with dry age-related macular degeneration.
Xelafaslatide, formerly known as ONL1204, is a small-molecule Fas inhibitor designed to protect key retinal cells from cell death.
Xelafaslatide is a small-molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across multiple retinal diseases and conditions.
The company announced that xelafaslatide is the newly established nonproprietary name for ONL1204 Ophthalmic Solution, following approval from the World Health Organization and the United States Adopted Names Council.
Author's summary: ONL Therapeutics starts phase 2 trial for xelafaslatide.
More News
- Obituaries – Week of Oct. 27, 2025 - The Observer
- Mike Brown is quickly reaching a crushing realization Knicks fans already knew
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- 2025 Victoria Derby Field & Betting Update: All Eyes on Observer - races.com.au
- Reneé Rapp Is Officially Heading Down Under Next Year - Star Observer
- How NGOs die — Europe's playbook for dismantling democracy
- Today's weather in Frome - 28 October